Introduction
ALS
The efficacy and safety of an oral, fixed‐dose combination of sodium phenylbutyrate and taurursodiol (PB and TURSO [RELYVRIOOLE phases provide an opportunity for longer‐term assessment of survival outcomes in trials with randomized placebo‐controlled phases of short duration in addition to increasing access to investigational therapies for people living with fatal conditions such as ALS. However, placebo‐to‐active crossover in trials incorporating OLE phases may lead to underestimation of the effect of these therapies on overall survival in ITT analyses.The Pooled Resource Open‐Access ALS Clinical Trials (PRO‐ACT) database is a robust resource of open‐access data relating to clinical outcomes in ALS,